Recent developments in anti-angiogenic and vascular-disrupting therapies as well as hypofractionated radiotherapy have shown the great potential of tumor vasculature as a therapeutic target for cancer medicine. We have an original idea for using targeted gold nanoparticles as vascular disruptive agents (VDA) in conjunction with clinical megavoltage photon beams. Unlike competing proposals, we recognize that gold nanoparticles tend to accumulate in, and can even be targeted for, tumor blood vessels and that these structures may be more important for anti-cancer therapy than clonogenic cell death. Due to the short distance traveled by x-ray induced photoelectrons, the endothelial cells of the tumor will receive a sizable boost in dose, even for clinical megavoltage photon irradiation. We are proposing a therapy that would be highly compatible with current clinical practice and could offer a substantial clinical benefit. Upon the successful completion of the aims, we will have demonstrated the validity of two underlying premises: 1) gold nanoparticles can be effectively, and safely, targeted to the tumor endothelium, and 2) the incidence of endothelial cell apoptosis during radiotherapy will be highly correlated to the proximity and local concentrations of gold nanoparticles.

Public Health Relevance

The goal of this project is the improvement of cancer therapy by employing gold nanoparticles, specifically targeted to tumor blood vessels, during radiation therapy. These nanoparticles will give off an extra radiation dose to their immediate surroundings during therapeutic irradiation. The ensuing collapse of the tumor vasculature could lead to large scale cancer cell death and potentially halt metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA164645-02
Application #
8507641
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Capala, Jacek
Project Start
2012-07-09
Project End
2014-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$79,809
Indirect Cost
$27,592
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Berbeco, Ross I; Detappe, Alexandre; Tsiamas, Panogiotis et al. (2016) Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy. Med Phys 43:436
Schuemann, Jan; Berbeco, Ross; Chithrani, Devika B et al. (2016) Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. Int J Radiat Oncol Biol Phys 94:189-205
Kunjachan, Sijumon; Detappe, Alexandre; Kumar, Rajiv et al. (2015) Nanoparticle Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy. Nano Lett 15:7488-96
Ngwa, Wilfred; Kumar, Rajiv; Sridhar, Srinivas et al. (2014) Targeted radiotherapy with gold nanoparticles: current status and future perspectives. Nanomedicine (Lond) 9:1063-82
Kumar, Rajiv; Korideck, Houari; Ngwa, Wilfred et al. (2013) Third generation gold nanoplatform optimized for radiation therapy. Transl Cancer Res 2:
Detappe, Alexandre; Tsiamas, Panagiotis; Ngwa, Wilfred et al. (2013) The effect of flattening filter free delivery on endothelial dose enhancement with gold nanoparticles. Med Phys 40:031706